Metabolomic profiles of 38 acylcarnitines in major depressive episodes before and after treatment

dc.contributor.authorAit Tayeb, Abd El Kader
dc.contributor.authorColle, Romain
dc.contributor.authorChappell, Kenneth
dc.contributor.authorEl-Asmar, Khalil
dc.contributor.authorAcquaviva-Bourdain, Cécile
dc.contributor.authorDavid, Denis J.
dc.contributor.authorTrabado, Sévérine Dsign©verine
dc.contributor.authorChanson, Philippe
dc.contributor.authorFève, Bruno
dc.contributor.authorBecquemont, Laurent
dc.contributor.authorVerstuyft, Céline
dc.contributor.authorCorruble, Emmanuelle
dc.contributor.departmentEpidemiology and Population Health (EPHD)
dc.contributor.facultyFaculty of Health Sciences (FHS)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:35:05Z
dc.date.available2025-01-24T11:35:05Z
dc.date.issued2023
dc.description.abstractBackground Major depression is associated with changes in plasma L-carnitine and acetyl-L-carnitine. But its association with acylcarnitines remains unclear. The aim of this study was to assess metabolomic profiles of 38 acylcarnitines in patients with major depression before and after treatment compared to healthy controls (HCs). Methods Metabolomic profiles of 38 plasma short-, medium-, and long-chain acylcarnitines were performed by liquid chromatography-mass spectrometry in 893 HCs from the VARIETE cohort and 460 depressed patients from the METADAP cohort before and after 6 months of antidepressant treatment. Results As compared to HCs, depressed patients had lower levels of medium- and long-chain acylcarnitines. After 6 months of treatment, increased levels of medium- and long-chain acyl-carnitines were observed that no longer differed from those of controls. Accordingly, several medium- and long-chain acylcarnitines were negatively correlated with depression severity. Conclusions These medium- and long-chain acylcarnitine dysregulations argue for mitochondrial dysfunction through fatty acid β-oxidation impairment during major depression. © The Author(s), 2023. Published by Cambridge University Press.
dc.identifier.doihttps://doi.org/10.1017/S003329172300140X
dc.identifier.eid2-s2.0-85184290434
dc.identifier.pmid37226550
dc.identifier.urihttp://hdl.handle.net/10938/28292
dc.language.isoen
dc.publisherCambridge University Press
dc.relation.ispartofPsychological medicine
dc.sourceScopus
dc.subjectAcylcarnitines
dc.subjectAntidepressant
dc.subjectFatty acid oxidation
dc.subjectMajor depressive disorder
dc.subjectMajor depressive episode
dc.subjectMitochondria
dc.titleMetabolomic profiles of 38 acylcarnitines in major depressive episodes before and after treatment
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2023-746.pdf
Size:
337.74 KB
Format:
Adobe Portable Document Format